Methylene blue photodynamic therapy in malignant melanoma decreases expression of proliferating cell nuclear antigen and heparanases

Clinical and Experimental Dermatology

Volumn 37, Issue 5, 2012, Pages 527-533

  Wagner, M ^a   Suarez, E R ^a,b   Theodoro, T R ^a   Machado Filho, C D A S ^a   Gama, M F M ^a   Tardivo, J P ^a   Paschoal, F M ^a   Pinhal, Maria Aparecida Da Silva ^a,b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; HEPARANASE; METHYLENE BLUE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR WEIGHT; WEIGHT;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; GLUCURONIDASE; IMMUNOHISTOCHEMISTRY; MELANOMA, EXPERIMENTAL; METHYLENE BLUE; MICE; MICE, NUDE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROLIFERATING CELL NUCLEAR ANTIGEN; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862887782     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2011.04291.x     Document Type: Article

References (24)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004; 150: 179-85. (Pubitemid 38352453)
2. Link EM. Targeting melanoma with 211At/131I-methylene blue. preclinical and clinical experience. Hybridoma 1999; 18: 77-82. (Pubitemid 29140425)
3. Almeida RD, Manadas BJ, Carvalho AP, Duarte CB. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004; 1704: 59-86.
4. Dougherty TJ, Gomer CJ, Henderson BW et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-905. (Pubitemid 28304157)
5. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J Am Acad Dermatol 2000; 42: 389-413.
6. Tardivo J, Giglio AD, Paschoal L et al. Treatment of melanoma lesions using methylene blue and RL50 light source. Photodiagn Photodyn Ther 2004; 1: 345-6. (Pubitemid 40460322)
7. Tardivo J, Giglio A, Oliveira C et al. Methylene blue in photodynamic therapy: from basic mechanisms to clinical applications. Photodiagn Photodyn Ther 2005; 2: 175-91. (Pubitemid 41751085)
8. Rivera RS, Nagatsuka H, Siar CH et al. Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma. Oncol Rep 2008; 19: 657-61. (Pubitemid 351330432)
9. Reiland J, Kempf D, Roy M et al. FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia 2006; 8: 596-606. (Pubitemid 44061315)
10. Suarez ER, Nohara AS, Mataveli FD et al. Glycosaminoglycan synthesis and shedding induced by growth factors are cell and compound specific. Growth Factors 2007; 25: 50-9. (Pubitemid 46672286)
11. Baker E, Crawford J, Sutherland GR et al. Human HPA endoglycosidase heparanase map position 4q21.3. Chromosome Res 1999; 7: 319. (Pubitemid 29353707)
12. Vlodavsky I, Goldshmidt O. Properties and function of heparanase in cancer metastasis and angiogenesis. Haemostasis, 2001; 31: Suppl.
13. McKenzie E, Tyson K, Stamps A et al. Cloning and expression of profiling of HPA2, a novel mammalian heparanase family member. Biochem Biophys Res Comm 2000; 276: 1170-7.
14. Foster H, Small D, Fox G. The Mouse in Biomedical Research. New York: Academic Press, 1983.
15. Matos LL, Stabenow E, Tavares MR et al. Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis. Clinics (São Paulo) 2006; 61: 417-24.
16. Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008; 53: R61-109.
17. Choudhary S, Nouri K, Elsaie ML. Photodynamic therapy in dermatology: a review. Lasers Med Sci 2009; 24: 971-80.
18. Link EM, Brown I, Carpenter RN, Mitchell JS. Uptake and therapeutic effectiveness of 125I- and 211At-methylene blue for pigmented melanoma in an animal model system. Cancer Res 1989; 49: 4332-7. (Pubitemid 19207282)
19. Noodt BB, Rodal GH, Wainwright M et al. Apoptosis induction by different pathways with methylene blue derivative and light from mitochondrial sites in V79 cells. Int J Cancer 1998; 75: 941-8. (Pubitemid 28134121)
20. Chen Y, Zheng W, Li Y et al. Apoptosis induced by methylene-blue-mediated photodynamic therapy in melanomas and the involvement of mitochondrial dysfunction revealed by proteomics. Cancer Sci 2008; 99: 2019-27.
21. Peretti T, Waisberg J, Mader AM et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur J Gastroenterol Hepatol 2008; 20: 756-65.
22. Mahtouk K, Hose D, Raynaud P et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007; 109: 4914-23. (Pubitemid 46827789)
23. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008; 283: 32628-36.
24. Goldshmidt O, Zcharia E, Cohen M et al. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 2003; 17: 1015-25. (Pubitemid 36676388)